Name: Summary of the probe development efforts to identify inhibitors of human diacylglycerol lipase, beta (DAGLB). ..more
Target
Depositor Specified Assays
Show more |
| AID | Name | Type | Comment |
|---|---|---|---|
| 504411 | Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB) | screening | Primary screen (DAGLB inhibitors in singlicate) |
| 504445 | Fluorescence-based biochemical high throughput confirmation assay for inhibitors of human diacylglycerol lipase, beta (DAGLB) | screening | Confirmation screen (DAGLB inhibitors in triplicate) |
| 602311 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in mouse brain membrane in vitro set 1 | other | Late stage assay (serine hydrolases in mouse brain membrane inhibitors in vitro) |
| 602312 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of recombinant anti-target ABHD11 in vitro set 2 | other | Late stage assay (ABHD11 inhibitors in vitro) |
| 602319 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of antitarget ABHD6 in vitro | other | Late stage assay (ABHD6 inhibitors in vitro) |
| 602320 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of DAGLb in vitro | confirmatory | Late stage assay (DAGLb inhibitors in vitro in triplicate) |
| 602321 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in mouse brain membrane in vitro set 3 | other | Late stage assay (serine hydrolases in mouse brain membrane inhibitors in vitro) |
| 602322 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of antitarget ABHD6 in vitro | confirmatory | Late stage assay (ABHD6 inhibitors in vitro in triplicate) |
| 602323 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in mouse brain membrane in vitro set 2 | other | Late stage assay (serine hydrolases in mouse brain membrane inhibitors in vitro) |
| 602299 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of overexpressed DAGLb in vitro set 2 | other | Late stage assay (overexpressed DAGLb inhibitors in vitro) |
| 602300 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of overexpressed DAGLb in vitro set 3 | other | Late stage assay (overexpressed DAGLb inhibitors in vitro) |
| 602301 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of recombinant anti-target ABHD11 in vitro set 1 | other | Late stage assay (ABHD11 inhibitors) |
| 602302 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of overexpressed DAGLb in vitro set 1 | other | Late stage assay (overexpressed DAGLb inhibitors in vitro) |
| 602303 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of overexpressed DAGLb in vitro; triazole urea library | other | Late stage assay (overexpressed DAGLb inhibitors in vitro; triazole urea library) |
| 602335 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of anti-target ABHD6 in situ | confirmatory | Late stage assay (ABHD6 inhibitors in situ in triplicate) |
| 602337 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): absorbance-based cell-based dose response assay to determine cytotoxicity of inhibitor compounds | confirmatory | Late stage dose response assay (cytotoxicity in five replicates) |
| 602339 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis | other | Late stage assay (DAGLb SILAC selectivity analysis) |
| 602341 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based cell-based Activity-Based Protein Profiling (ABPP) SILAC selectivity analysis for ABHD6 | other | Late stage assay (ABHD6 SILAC selectivity analysis) |
| 602343 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse brain ABHD6 in vivo, set 2 | other | Late stage assay (mouse brain ABHD6 inhibitors in vivo) |
| 602345 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse macrophage DAGLb in vivo | other | Late stage assay (mouse macrophage DAGLb inhibitors in vivo in duplicate) |
| 602347 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse brain ABHD6 in vivo | other | Late stage assay (mouse brain ABHD6 inhibitors in vivo in duplicate) |
| 602349 | Late stage assay provider results from the probe development effort to identify inhibitors of DAGLb: fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) assay to distinguish systemic and peripheral inhibitors | other | Late stage assay (distinguish systemic and peripheral inhibitors in duplicate) |
| 602351 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based animal-based Activity-Based Protein Profiling (ABPP) MudPIT selectivity analysis for ABHD6 | other | Late stage assay (ABHD6 MudPIT selectivity analysis in triplicate) |
| 602353 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based animal-based Activity-Based Protein Profiling (ABPP) MudPIT selectivity analysis | other | Late stage assay (DAGLb MudPIT selectivity analysis in triplicate) |
| 602354 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical dose-response gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of DAGLb in situ | confirmatory | Late stage dose-response (DAGLb inhibitors in situ in triplicate) |
| 602355 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of serine hydrolases in vitro | other | Late stage assay (serine hydrolases inhibitors in vitro) |
| 602403 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of recombinant antitarget DAGLa in vitro | other | Late stage assay (recombinant DAGLa inhibitors in vitro) |
| 602415 | Assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LC/MS-based biochemical inhibition of overexpressed DAGLb substrate turnover in vitro | other | Late stage assay (DAGLb substrate turnover inhibitors in vitro) |
| 624039 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based dose-response biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of antitarget ABHD6 in vitro, set 2 | confirmatory | Late stage assay (ABHD6 inhibitors in vitro) |
| 624041 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse liver ABHD6 in vivo | other | Late stage assay (mouse liver ABHD6 inhibitors in vivo) |
| 624077 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of mouse liver ABHD6 in vivo upon oral compound administration | other | Late stage assay (mouse liver ABHD6 inhibitors in vivo upon oral compound administration) |
| 624468 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): LCMS-based biochemical dose response assay | confirmatory | Late stage dose response (DAGLb inhibitors in duplicate) |
| 624472 | Late stage assay provider results from the probe development effort to identify inhibitors of diacylglycerol lipase, beta (DAGLb): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition of DAGLb by enantiomers of KT116 | other | Late stage assay (DAGLb inhibition by enantiomers of KT116) |
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Benjamin Cravatt, The Scripps Research Institute (TSRI)
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 DA025285
Grant Proposal PI: Benjamin Cravatt, The Scripps Research Institute (TSRI)
External Assay ID: DAGLB_INH_ SUMMARY
Name: Summary of the probe development efforts to identify inhibitors of human diacylglycerol lipase, beta (DAGLB).
Description:
Endocannabinoids (ECs) represent a unique group of lipids that function as chemical messengers in the nervous system. To date, the two principle ECs identified in mammals are N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoyl-glycerol (2-AG). They have been implicated in various physiological and pathological functions including appetite, pain, sensation, memory, and addiction (1). Unlike traditional neurotransmitters, which are stored in vesicles, ECs are synthesized and released on demand, and then rapidly degraded to terminate signaling. Thus, the metabolic pathways that govern EC turnover are critical in determining the magnitude and duration of neuronal signaling events (2). Endocannabinoid biosynthesis, in contrast to degradation, is poorly understood. Recently, two serine hydrolases, DAGL-a and -B, were cloned and found to selectively cleave sn-1 acyl chains from diacylglycerols (DAG) to generate 2-AG in vitro (3). Their function in the nervous system was validated in vivo by the generation of DAGL-a and -B knock-out mice (4, 5). However, it is still unclear to what extent DAGL-a/B catalytic activity contributes to 2-AG-mediated signaling. The development of potent and selective inhibitors would offer a means to perturb DAGL-a/B activity in a selective, reversible, and temporally-controlled manner. Given the non-selective nature of current DAGL-a/B inhibitors (6), specific chemical probes would serve as invaluable tools to delineate DAGL-a/B function in 2-AG signaling networks of the brain.
Summary of Probe Development Effort:
This probe development effort is focused on the identification of inhibitors of human diacylglycerol lipase, beta (DAGLB). All AIDs that contain results associated with this project can be found in the "Related Bioassays" section of this Summary AID.
References:
1. Di Marzo, V. (2008) Targeting the endocannabinoid system: to enhance or reduce?, Nat Rev Drug Discov 7, 438-455.
2. Ahn, K., McKinney, M. K., and Cravatt, B. F. (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system, Chem Rev 108, 1687-1707.
3. Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E. J., Gangadharan, U., Hobbs, C., Di Marzo, V., and Doherty, P. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain, J Cell Biol 163, 463-468.
4. Gao, Y., Vasilyev, D. V., Goncalves, M. B., Howell, F. V., Hobbs, C., Reisenberg, M., Shen, R., Zhang, M. Y., Strassle, B. W., Lu, P., Mark, L., Piesla, M. J., Deng, K., Kouranova, E. V., Ring, R. H., Whiteside, G. T., Bates, B., Walsh, F. S., Williams, G., Pangalos, M. N., Samad, T. A., and Doherty, P. (2010) Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice, J Neurosci 30, 2017-2024.
5. Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., Sakimura, K., and Kano, M. (2010) The Endocannabinoid 2-Arachidonoylglycerol Produced by Diacylglycerol Lipase +/- Mediates Retrograde Suppression of Synaptic Transmission, Neuron 65, 320-327.
6. Hoover, H. S., Blankman, J. L., Niessen, S., and Cravatt, B. F. (2008) Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling, Bioorganic & Medicinal Chemistry Letters 18, 5838-5841.
Keywords:
Summary, Summary AID, Diacylglycerol lipase, Diacylglycerol lipase-beta, DAGL, DAGL-b, DAGL-beta, DAGLB, DAGL-B, hydrolase, serine hydrolase, appetite, pain, sensation, memory, addiction, fluorescence, HEK293T, membrane, lysate, EnzChek, fluorogenic lipase substrate, inhibitor, confirmation, triplicate, uHTS, HTS, 1536, high throughput screen, Scripps, Scripps Florida, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Benjamin Cravatt, The Scripps Research Institute (TSRI)
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R01 DA025285
Grant Proposal PI: Benjamin Cravatt, The Scripps Research Institute (TSRI)
External Assay ID: DAGLB_INH_ SUMMARY
Name: Summary of the probe development efforts to identify inhibitors of human diacylglycerol lipase, beta (DAGLB).
Description:
Endocannabinoids (ECs) represent a unique group of lipids that function as chemical messengers in the nervous system. To date, the two principle ECs identified in mammals are N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoyl-glycerol (2-AG). They have been implicated in various physiological and pathological functions including appetite, pain, sensation, memory, and addiction (1). Unlike traditional neurotransmitters, which are stored in vesicles, ECs are synthesized and released on demand, and then rapidly degraded to terminate signaling. Thus, the metabolic pathways that govern EC turnover are critical in determining the magnitude and duration of neuronal signaling events (2). Endocannabinoid biosynthesis, in contrast to degradation, is poorly understood. Recently, two serine hydrolases, DAGL-a and -B, were cloned and found to selectively cleave sn-1 acyl chains from diacylglycerols (DAG) to generate 2-AG in vitro (3). Their function in the nervous system was validated in vivo by the generation of DAGL-a and -B knock-out mice (4, 5). However, it is still unclear to what extent DAGL-a/B catalytic activity contributes to 2-AG-mediated signaling. The development of potent and selective inhibitors would offer a means to perturb DAGL-a/B activity in a selective, reversible, and temporally-controlled manner. Given the non-selective nature of current DAGL-a/B inhibitors (6), specific chemical probes would serve as invaluable tools to delineate DAGL-a/B function in 2-AG signaling networks of the brain.
Summary of Probe Development Effort:
This probe development effort is focused on the identification of inhibitors of human diacylglycerol lipase, beta (DAGLB). All AIDs that contain results associated with this project can be found in the "Related Bioassays" section of this Summary AID.
References:
1. Di Marzo, V. (2008) Targeting the endocannabinoid system: to enhance or reduce?, Nat Rev Drug Discov 7, 438-455.
2. Ahn, K., McKinney, M. K., and Cravatt, B. F. (2008) Enzymatic pathways that regulate endocannabinoid signaling in the nervous system, Chem Rev 108, 1687-1707.
3. Bisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E. J., Gangadharan, U., Hobbs, C., Di Marzo, V., and Doherty, P. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain, J Cell Biol 163, 463-468.
4. Gao, Y., Vasilyev, D. V., Goncalves, M. B., Howell, F. V., Hobbs, C., Reisenberg, M., Shen, R., Zhang, M. Y., Strassle, B. W., Lu, P., Mark, L., Piesla, M. J., Deng, K., Kouranova, E. V., Ring, R. H., Whiteside, G. T., Bates, B., Walsh, F. S., Williams, G., Pangalos, M. N., Samad, T. A., and Doherty, P. (2010) Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice, J Neurosci 30, 2017-2024.
5. Tanimura, A., Yamazaki, M., Hashimotodani, Y., Uchigashima, M., Kawata, S., Abe, M., Kita, Y., Hashimoto, K., Shimizu, T., Watanabe, M., Sakimura, K., and Kano, M. (2010) The Endocannabinoid 2-Arachidonoylglycerol Produced by Diacylglycerol Lipase +/- Mediates Retrograde Suppression of Synaptic Transmission, Neuron 65, 320-327.
6. Hoover, H. S., Blankman, J. L., Niessen, S., and Cravatt, B. F. (2008) Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling, Bioorganic & Medicinal Chemistry Letters 18, 5838-5841.
Keywords:
Summary, Summary AID, Diacylglycerol lipase, Diacylglycerol lipase-beta, DAGL, DAGL-b, DAGL-beta, DAGLB, DAGL-B, hydrolase, serine hydrolase, appetite, pain, sensation, memory, addiction, fluorescence, HEK293T, membrane, lysate, EnzChek, fluorogenic lipase substrate, inhibitor, confirmation, triplicate, uHTS, HTS, 1536, high throughput screen, Scripps, Scripps Florida, Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Panel Information
Assays
§ Panel component ID.
| Data Table(Active) Data Table(All) | Show more |
| PID§ | Name | Substance | Panel Targets | Description | Additional Information | ||
|---|---|---|---|---|---|---|---|
| Active | Inactive | ||||||
| 1 | AID 602322_1 | monoacylglycerol lipase ABHD6 [Mus musculus] [gi:31560264] | Taxonomy id: 10090 Gene id: 66082 | ||||
| 2 | AID 602322_2 | sn1-specific diacylglycerol lipase beta [Mus musculus] [gi:31559956] | Taxonomy id: 10090 Gene id: 231871 | ||||
| 3 | AID 602335_1 | monoacylglycerol lipase ABHD6 [Mus musculus] [gi:31560264] | Taxonomy id: 10090 Gene id: 66082 | ||||
| 4 | AID 602335_2 | sn1-specific diacylglycerol lipase beta [Mus musculus] [gi:31559956] | Taxonomy id: 10090 Gene id: 231871 | ||||
| 5 | AID 602337_1 | ||||||
| 6 | AID 602337_2 | ||||||
| 7 | AID 602320 | sn1-specific diacylglycerol lipase beta [Mus musculus] [gi:31559956] | Taxonomy id: 10090 Gene id: 231871 | ||||
| 8 | AID 602354_1 | sn1-specific diacylglycerol lipase beta [Mus musculus] [gi:31559956] | Taxonomy id: 10090 Gene id: 231871 | ||||
| 9 | AID 602354_2 | monoacylglycerol lipase ABHD6 [Mus musculus] [gi:31560264] | Taxonomy id: 10090 Gene id: 66082 | ||||
| 10 | AID 624039 | sn1-specific diacylglycerol lipase beta [Mus musculus] [gi:31559956] | Taxonomy id: 10090 Gene id: 231871 | ||||
| 11 | AID 624468 | sn1-specific diacylglycerol lipase beta [Mus musculus] [gi:31559956] | Taxonomy id: 10090 Gene id: 231871 | ||||
§ Panel component ID.
Result Definitions
| Show more |
| TID | Name | Description | PID§ | Panel Targets | Histogram | Type | Unit | |
|---|---|---|---|---|---|---|---|---|
| Outcome | The BioAssay activity outcome | Outcome | ||||||
| Score | The BioAssay activity ranking score |  | Integer | |||||
| 1 | ML # | Unique alphanumeric identifier assigned to a chemical probe molecule within the Molecular Libraries Probe Production Centers Network (MLPCN). | String | |||||
| 2 | IC50 [AID 602322_1]* | The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar. | 1 | monoacylglycerol lipase ABHD6 [Mus musculus] | | Float | μM | |
| 3 | Qualifier [AID 602322_2] | Qualifier identifies if the resultant IC50 was determined manually to be less than or greater than its listed IC50. | 2 | sn1-specific diacylglycerol lipase beta [Mus musculus] | String | |||
| 4 | IC50 [AID 602322_2]* | The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar. | 2 | | Float | μM | ||
| 5 | IC50 [AID 602335_1]* | The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar. | 3 | monoacylglycerol lipase ABHD6 [Mus musculus] | | Float | μM | |
| 6 | Qualifier [AID 602335_2] | Qualifier identifies if the resultant IC50 was determined manually to be less than or greater than its listed IC50. | 4 | sn1-specific diacylglycerol lipase beta [Mus musculus] | String | |||
| 7 | IC50 [AID 602335_2]* | The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar. | 4 | | Float | μM | ||
| 8 | Qualifier [AID 602337_1] | Qualifier identifies if the resultant CC50 was determined manually to be greater than its listed CC50. | 5 | String | ||||
| 9 | CC50 [AID 602337_1]* | The value for the concentration at which 50% of surviving cells are observed in serum-free medium; CC50 shown in micromolar. | 5 | | Float | μM | ||
| 10 | CC50 [AID 602337_2]* | The value for the concentration at which 50% of surviving cells are observed in serum-containing medium; CC50 shown in micromolar. | 6 | | Float | μM | ||
| 11 | Average IC50 [AID 602320]* | The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar. | 7 | sn1-specific diacylglycerol lipase beta [Mus musculus] | | Float | μM | |
| 12 | Average IC50 [AID 602354_1]* | The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar. | 8 | sn1-specific diacylglycerol lipase beta [Mus musculus] | | Float | μM | |
| 13 | Average IC50 [AID 602354_2]* | The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar. | 9 | monoacylglycerol lipase ABHD6 [Mus musculus] | | Float | μM | |
| 14 | Average IC50 [AID 624039]* | The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar. | 10 | sn1-specific diacylglycerol lipase beta [Mus musculus] | | Float | μM | |
| 15 | Average IC50 [AID 624468]* | The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar. | 11 | sn1-specific diacylglycerol lipase beta [Mus musculus] | | Float | μM |
* Activity Concentration. § Panel component ID.
Additional Information
Grant Number: 1 R01 DA025285
Classification
PageFrom: